MiMedx Group, Inc. (MDXG)
| Market Cap | 983.86M |
| Revenue (ttm) | 256.09M |
| Net Income (ttm) | -72.75M |
| Shares Out | 108.49M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $8.88 |
| Previous Close | $8.82 |
| Change ($) | 0.06 |
| Change (%) | 0.68% |
| Day's Open | 8.80 |
| Day's Range | 8.72 - 9.01 |
| Day's Volume | 322,438 |
| 52-Week Range | 5.78 - 10.31 |
Persistent and sustained institutional buying in MiMedx should not be ignored as heavy hitters position themselves for key knee osteoarthritis data in 2021. Sales and revenue growth after two ...
Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designati...
Experienced Healthcare Executive Will Expand Company's Visibility Within the Financial Community
MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, t...
MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&...
MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, t...
MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, t...
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2020 Results - Earnings Call Transcript
Third Quarter Net Sales of $64 . 3 M illion , Above Preliminary Range
MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company,...
Only Amniotic Product Covered Under Updated Commercial Policy
MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company,...
MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company,...
MARIETTA, Ga., Oct. 15, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company,...
Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally
Third Quarter 2020 Net Sales Expected to be Between $61 Million - $64 Million
Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders
New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade
MARIETTA, Ga., Aug. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biolog...
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q2 2020 Results - Earnings Call Transcript
Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities
Strategic Leader with Proven Record of Delivering Growth and Business Transformation Strategic Leader with Proven Record of Delivering Growth and Business Transformation
MiMedx Fixes Cash Concerns With Relisting Right Around The Corner
Annual Report on Form 10-K includes Audited Financial Results for 2019
Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management
March Flowers Could Bring MiMedx Showers Of Shareholder Returns
MiMedx Group Inc. MDXG, +0.08% said Tuesday it has reached a settlement with the Securities and Exchange Commission to resolve a probe of its accounting practices.
A timetable of upcoming catalysts points to impressive upside potential by the end of 2019 and the beginning of 2020.
August starts the watch for restatements of MiMedx's financials possibly right before the company's yet to be scheduled 2019 Annual Meeting.
The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.
The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.
The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.
Annual meeting on June 17th will be an inflection point for the company with former CEO Petit either embraced or shunned by MiMedx shareholders.
Strong volume and sustained price action are a great signal for investors for very good reasons.
A new board could signify the start of a turnaround.
MiMedx Group Inc. said Thursday it would be overhauling its board of directors, a decision the company said it made in cooperation with one of its largest shareholders, Prescience Point Capita...
MiMedx Group Inc can't seem to leave controversy behind. Even as the company announced the conclusion of an independent audit committee investigation into some of its business practices, a new...
News about the former CEO Pete Petit is not enough of a reason to justify the recent sell-off in MiMedx stock.
About MDXG
MiMedx Group, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include EpiFix, a semi-permeable protective barrier membrane product used for the tr... [Read more...]
| Industry Medical Devices | |
| CEO Timothy R. Wright | Employees 696 |
| Stock Exchange NASDAQ | Ticker Symbol MDXG |
Financial Performance
In 2019, MiMedx Group's revenue was $299.26 million, a decrease of -16.67% compared to the previous year's $359.11 million. Losses were -$25.58 million, -14.67% less than in 2018.